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Abstract
Background: Tuberculosis is endemic to developing countries like India. Though the whole
genome sequences of the type strain M. tuberculosis H37Rv and the clinical strain M. tuberculosis
CDC1551 are available, the clinical isolates from India have not been studied extensively at the
genome level. This study was carried out in order to have a better understanding of isolates from
Kerala, a state in southern India.
Results:  A PCR based strategy was followed making use of the deletion region primers to
understand the genome level differences between the type strain H37Rv and the clinical isolates of
M. tuberculosis from Kerala. PCR analysis of patient isolates using RD1 region primers revealed the
amplification of a 386 bp region, in addition to the expected 652 bp amplicon. Southern
hybridization of genomic DNA with the 386 bp amplicon confirmed the presence of this new region
in a majority of the patient isolates from Kerala. Sequence comparison of this amplicon showed
close homology with the moaA3 gene of M. bovis. In M. bovis this gene is present in the RvD5 region,
an IS6110 mediated deletion that is absent in M. tuberculosis H37Rv.
Conclusion: This study demonstrates the presence of moaA3 gene, that is absent in M. tuberculosis
H37Rv and H37Ra, in a large number of local isolates. Whether the moaA3 gene provides any
specific advantage to the field isolates of the pathogen is unclear. Field strains from Kerala have
fewer IS6110 sequences and therefore are likely to have fewer IS6110 dependent rearrangements.
But as deletions and insertions account for much of the genomic diversity of M. tuberculosis, the
mechanisms of formation of sequence polymorphisms in the local isolates should be further
examined. These results suggest that studies should focus on strains from endemic areas to
understand the complexities of this pathogen.
Background
Tuberculosis remains one of the most life threatening dis-
eases and has been declared as a global emergency in 1993
by the World Health Organization (WHO) [1]. Failure in
adhering to the strict drug regimen has led to the emer-
gence of multi drug resistant isolates of this pathogen.
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This, combined with the problem of HIV, worsens the TB
menace in developing countries. However, the main rea-
son for the failure to eradicate tuberculosis lies in the bio-
logical properties of the infecting organism and its ability
to persist in a latent state in the macrophages.
Bacterial strains within a single species exhibit variations
in their properties such as pathogenicity, host specificity,
virulence, adaptation to particular habitats and drug
resistance. The passaging of M. tuberculosis H37Rv and M.
bovis  BCG for several decades outside the human host
have induced changes in the genome of the pathogen and
have also altered their virulence characteristics. Whole
genome sequences of the type strain M. tuberculosis H37Rv
[2], the clinical strain M. tuberculosis CDC1551 [3] and M.
bovis [4] are already available. Many researchers have used
a number of comparative analysis techniques like subtrac-
tive hybridization and microarray to identify differences
in the genomes of laboratory strains and vaccine strains.
Three genomic regions which are absent in M. bovis BCG
but present in M. bovis and  M. tuberculosis were first
described using subtractive hybridization [5]. DNA micro-
array based studies between H37Rv and BCG have shown
that 16 RDs (Regions of Differences) are deleted in BCG
[6]. Similarly, whole genome comparison studies have
shown six deletion regions in M. tuberculosis H37Rv –
RvD1 to RvD5 and TbD1 [7].
Our earlier studies on the clinical isolates from Kerala on
IS6110 polymorphism have shown that a large number of
isolates have few or no copy of the sequence [8]. This
made about fifty percent of strains untypable using
IS6110. These results have been corroborated by studies
from other endemic areas in India as well as outside [9-
12]. This has prompted us to speculate on whether there
are major differences in the genome in the field strains
from endemic areas. Therefore, we examined these strains
to see the distribution of the different RD regions. Here we
report the presence of a genomic region in the clinical iso-
lates of M. tuberculosis, which is absent in the type strains
H37Rv and H37Ra.
Methods
Mycobacterial strains and DNA isolation
The type strains used for the study included Mycobacterium
tuberculosis H37Rv, H37Ra and M. bovis BCG. These were
grown in Middlebrook 7H9 Broth (Difco Laboratories)
supplemented with OADC enrichment (Difco Laborato-
ries) and 0.05% glycerol (USB Corporation). Field strains
of Mycobacterium tuberculosis were those isolated from spu-
tum samples of tuberculosis patients from different parts
of Kerala. The strains were biochemically tested for Cata-
lase, Niacin and Nitrate for identification. They were char-
acterised by IS6110 fingerprinting. Drug resistance pattern
was also studied using the four major frontline drugs viz,
isoniazid, rifampicin, ethambutol and streptomycin.
DNA was isolated from cells pelleted from liquid culture
using glass beads in a minibead beater. The DNA was pre-
cipitated after phenol:chloroform extraction using 3M
Sodium acetate (pH 5.2) and 100% ethanol and dissolved
in TE buffer, pH 8.0.
PCR amplification of RD1 region
Oligonucleotide primer pairs used for the study were
RD1DLa: 5'-AGA TGA AGA CCG ATG CCG CTA C -3' and
RD1DRa: 5'-CCC GTG TTT CGC TAT TCT ACG C-3'. PCR
was performed in a final volume of 30 µl using 1.25 units
of Taq DNA Polymerase (Promega Corporation) for each
reaction. After initial denaturation, amplification was
done using a PCR thermal cycler (BioRad) for 35 cycles of
94°C/40 sec, 64°C/1 min, 72°C/1 min followed by a
final extension of 72°C/7 min. To identify the flanking
PCR of clinical isolates of M. tuberculosis for RD1 region Figure 1
PCR of clinical isolates of M. tuberculosis for RD1 
region. Lane 1: 100 bp marker, lane 2: H37Rv, lane 3: 
H37Ra, lane 4: M. bovis BCG, lanes 5–24: Clinical isolates 
RGTB 29, 37, 40, 43, 55, 60, 70, 86, 87, 93, 95, 109, 110, 123, 
142, 144, 154, 167, 177, 193 respectively.
PCR of clinical isolates of M. tuberculosis for moaA3 gene Figure 2
PCR of clinical isolates of M. tuberculosis for moaA3 
gene. Lane 1: Marker- λ DNA double digest (EcoR I/Hind III), 
lane 2: H37Rv, lane 3: H37Ra, lane 4: M. bovis BCG, lanes 5–
24: Clinical isolates RGTB 29, 37, 40, 43, 55, 60, 70, 86, 87, 
93, 95, 109, 110, 123, 142, 144, 154, 167, 177, 193 respec-
tively, lane 25: Negative Control.BMC Infectious Diseases 2005, 5:81 http://www.biomedcentral.com/1471-2334/5/81
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sequences of the 386 bp region, another set of primers
were used (moaFP: 5'-CCCATCGTGGTCGTTCACC-3' and
moaRP: 5'-CGATGGCAGCGGTTTACAG-3') which was
expected to amplify a 1254 bp product.
Southern hybridization
Genomic DNA from M. tuberculosis H37Rv, H37Ra, M.
bovis BCG and the clinical isolates digested using EcoR I
(New England Biolabs) was separated on agarose gels,
transferred to nylon membrane (Hybond) and probed
with α32P [dCTP] labelled PCR product. After overnight
hybridization at 65°C, the blot was washed with increas-
ing stringency of SSC-SDS and exposed to an activated
Phosphor screen (Kodak). The screen was then scanned
using Personal Molecular Imager FX (BioRad) and the
picture was visualized using the software Quantity One
(BioRad).
Cloning and sequencing
PCR products separated on agarose gel were eluted using
GFX ™ PCR DNA and Gel Band Purification kit (Amer-
sham Pharmacia Biotech Inc). The eluted DNA was
cloned into pGEMT Easy vector (Promega Corporation).
Plasmid DNA for sequencing was purified using Nucleos-
pin Plasmid kit (Macherey-Nagel) in accordance with
manufacturers' instructions. Plasmids were digested with
EcoR I to check for the presence of inserts. DNA sequenc-
ing by cycle sequencing method with the fluorescent dye
terminator (Big Dye Terminator Cycle Sequencing Ready
Reaction Kit, (PE Biosystems)) was carried out with T7
and SP6 promoter primers in an automated sequencer
(ABI Prism 310).
Results
Screening of RD1 by PCR
RD1, the most significant region of difference between M.
tuberculosis and M. bovis BCG is a 9505 bp long region
absent in all the different BCG substrains. PCR primers
were designed to amplify regions within RD1 to find out
polymorphism between type strains and the clinical iso-
lates. PCR using RD1DLa and RD1DRa primers was
expected to amplify a 652 bp fragment (comprising of
Rv3874 and Rv3875, coding for cfp10 and esat 6) in M.
tuberculosis H37Rv and the clinical isolates. In H37Rv and
H37Ra the expected 652 bp band was observed. In BCG
the 652 bp band was absent as expected, but a 386 bp frag-
ment was amplified. The clinical isolates showed both
652 and 386 bp fragments. A set of twenty patient isolates
from Kerala was used for the initial screening. Of these,
only one isolate (RGTB43), did not have the 386 bp
amplicon. (Fig. 1). Later we screened a total of one hun-
dred isolates from Kerala by PCR and all except three
showed the presence of the 386bp amplicon (Data not
shown). A second PCR using primes designed from the
surrounding regions of moaA3 gene was done to confirm
the presence of the full ORF in clinical isolates. The
expected amplicon of 1254 bp was obtained in all those
clinical isolates which had the 386 bp fragment (Fig 2).
Southern blot
To confirm the results of the PCR, EcoR I digested genomic
DNA from M. bovis BCG,  M. tuberculosis H37Rv and
H37Ra and pooled DNA from all the 20 clinical isolates
(called local pool) were subjected to Southern hybridiza-
tion using radioactively labelled 386 bp fragment from M.
bovis BCG. Local pool and M. bovis BCG showed a signal
corresponding to about 1.0 kb (Fig. 3A) while H37Rv and
H37Ra were negative. Southern hybridization of each of
the individual clinical isolate was then carried out for con-
firming the result and all, except RGTB 43, showed a pos-
itive signal (Fig. 3B). The strain RGTB 43 was negative by
PCR as well.
DNA sequence homology
Sequencing of the 386 bp amplicon cloned into pGEMT
Easy vector was carried out using T7 and SP6 promoter
primers. The sequence data obtained was compared to the
whole genome of M. bovis [19]M. tuberculosis [20] and
100% sequence homology was obtained with M. bovis
whereas  M. tuberculosis H37Rv showed only 61%. The
upstream and downstream sequences of this 386 bp
region were identified by searching the M. bovis genome
database. It was found that the sequenced fragment did
not belong to the RD1 region. Instead, it was found to be
part of RvD5, a deletion in the type strain H37Rv (Fig. 4).
This region corresponds to moaA3 gene in M. bovis which
Southern hybridization of EcoR I digested genomic DNA  probed with radiolabelled 386 bp PCR product Figure 3
Southern hybridization of EcoR I digested genomic 
DNA probed with radiolabelled 386 bp PCR product. 
Panel A- Lane1: Marker – λ DNA double digest (EcoR I/Hind 
III) lane2: H37Rv, lane 3: H37Ra, lane 4: M. bovis BCG, lane 5: 
pool of DNA from local isolates. Panel B – Southern hybridi-
zation to DNA from individual isolates. Lane 1: Marker – λ 
DNA double digest (EcoR I/Hind III), lane 2: M. bovis BCG, 
Lanes 3–22: Isolates RGTB 70, 86, 87, 93, 95, 109, 110, 123, 
142, 144, 154, 167, 177, 193, 29, 37, 40, 43, 55, 60 
respectively.BMC Infectious Diseases 2005, 5:81 http://www.biomedcentral.com/1471-2334/5/81
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codes for molybdenum cofactor biosynthesis protein A,
MoaA1.
The moaA3 gene was present in 97 of the 100 clinical iso-
lates tested (details not presented). These isolates had var-
ying IS6110 and drug resistance profiles suggesting the
possible absence of a relationship between the moaA3
fragment, IS6110  copy number and drug resistance
profile.
Discussion
Studies using subtractive hybridization [5] and microar-
rays [6] have identified 16 regions, (ranging in size from
2–12.7 kb), in M. tuberculosis H37Rv which are absent in
M. bovis BCG. Deletions are also reported in H37Rv –
RvD1 to RvD5 and TbD1 [7]. These results suggest that
generation of deletions may be a major mechanism for
creating genetic diversity among the members of the com-
plex. On this basis, we sought to screen the clinical iso-
lates of M. tuberculosis from Kerala for differences in the
RD regions. Initially, we used primers spanning RD1
A diagrammatic representation of moaA3 and the surrounding regions Figure 4
A diagrammatic representation of moaA3 and the surrounding regions. Comparison of the region comprising 
moaA3 gene and the surrounding genes in M. bovis, H37Rv and the clinical isolate, CDC1551. All data from references [19, 20, 
21, 22]. The coamplified PCR product is shown as a thick line in the moaA3 locus. The amplicon extends from 575 to 960 of 
moaA3 gene in M. bovis. The genome coordinates of the moaA3 gene in M. bovis and M. tuberculosis CDC1551 are shown. The 
thin dotted lines indicate corresponding genes in M. bovis and CDC1551. The bold dotted lines indicate similar genes in 
CDC1551 and H37Rv. Rv3324A is differentially shown since it's a truncated gene and has only partial nucleotide similarity to 
CDC1551 moaB3 gene.
PCR product
575 to 960 of moaA3
M.bovis
Clinical isolate
CDC1551
moaC3 MT3426 moaA3 MT3427.1 MT3428 MT3429 MT3430 MT3431
moaC3 moaB3 moaA3 Mb3356 Mb3357 embR2 Mb3359 Mb3360 sigJ
moaC3 Rv3324A Rv3325 Rv3326 Rv3327 sigJ
H37Rv
3665238 3666302
3705604 3706791
moaA3 geneBMC Infectious Diseases 2005, 5:81 http://www.biomedcentral.com/1471-2334/5/81
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region, since RD1 is the most important region of
difference and is deleted in all the substrains of M. bovis
BCG [6]. The loss of RD1 is one major genetic event that
contributes to the attenuation of BCG, and its reintroduc-
tion into an attenuated strain resulted in a significant
increase in virulence [13].
Of the nine open reading frames predicted within the 9.5
kb RD1 region, ORFs coding for cfp10 and esat6 are con-
sidered to be very important as there is vigorous host
response to these proteins. Amplification using primers
that span this region was expected to give a 652 bp PCR
product. But the PCR results revealed an extra amplicon of
386 bp in the local isolates and BCG. Further characteriza-
tion by sequencing and homology search indicated that
this region is a part of the moaA3 gene which codes for
molybdopterin cofactor protein A in M. bovis. The
sequence of the 386 bp amplicon obtained from the local
strains showed 100% homology with M. bovis as com-
pared to 61% with M. tuberculosis H37Rv. The PCR prim-
ers that we made spanning the RD1 region was similar to
portions of the moaA3 gene in the RvD5 region, which
resulted in the amplification of the 386 bp fragment. This
amplicon spanned the nucleotides 575 to 960 of the
moaA3 gene in M. bovis (Fig 4). The moaA3 gene is absent
in H37Rv, but another gene in the biosynthetic pathway,
moaC3, was the closest to the 386 bp amplicon, with a
homology of 61%. Database searches revealed that the
moaA3 gene is present in the CDC1551 in the RvD5 region
as well. To confirm the location of the moaA3 gene in our
isolates, a second PCR designed to amplify the flanking
sequences of moaA3 gene was performed. The results con-
firmed the location of the moaA3 gene in the clinical iso-
lates from Kerala. In M. bovis (Mb3355) the gene is 1065
bp long while in CDC 1551, the moaA3 gene (MT3427) is
1189 bp long, due to an additional 123 bp in the C termi-
nal region. In the overlapping region, CDC1551 has
100% homology with M. bovis moaA3. Genome compari-
son studies have shown that moaA3 is one among the few
genes that is present in CDC1551 and absent in H37Rv
[3]. Southern hybridization studies done in our lab con-
firmed that moaA3 gene is absent in the type strains M.
tuberculosis H37Rv and H37Ra and is present in most of
the clinical isolates in Kerala as well as in M. bovis BCG.
Since moaA3 gene has been seen in the RvD5 region in
both M bovis and in CDC1551, we have presumed that
these genes are in the same region in our local strains as
well, but these results need confirmation. The regions sur-
rounding the moaA3 gene and the IS6110 elements flank-
ing the RvD5 region in these local isolates merit further
investigation.
Molybdopterin is a cofactor required for nitrate reductase
and many other enzymes involved in anaerobic metabo-
lism. Genes involved in the molybdopterin cofactor bio-
synthesis pathway are present in almost all organisms. M.
Table 1: Details of clinical isolates of M. tuberculosis. The resistance (R)/sensitivity(S) profile of the isolates to the four frontline anti- 
tuberculosis drugs and their IS6110 copy number are shown below.
RGTB No: Drug resistance profile IS6110 copy no:
Isoniazid Ethambutol Rifampicin Streptomycin
29 R R S S 1
3 7 SSSS1
4 0SRSS0
4 3SRSS9
55 R R S S 1
6 0 RRSR2
7 0 SSSS1
8 6RRRS1
87 R R S S 3
9 3 RSSS1
9 5 SSSS6
1 0 9 SSSS 1 2
110 R S S S 8
1 2 3 SSSS0
142 R R S R 10
1 4 4 SSSS1
1 5 4 RSRS1
167 S R S S 14
177 S R S S 1
193 R R R S 1BMC Infectious Diseases 2005, 5:81 http://www.biomedcentral.com/1471-2334/5/81
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tuberculosis H37Rv dedicates 21 genes to the biosynthesis
of this cofactor [2]. But there is no gene homologous to
the moaA3 found in M. bovis. This cofactor is thought to be
involved in the biosynthesis of molybdopterin precurser Z
from guanosine in M. bovis. Studies in Escherichia coli have
suggested that these molybdoenzymes have the ability to
hydroxylate or dehydroxylate certain compounds ena-
bling the bacteria to detoxify them [14]. In addition, E.
coli with defective moa show a decrease in the frequency of
adaptive mutations [15]. Thus, one may infer that the
moaA3 gene might have a role in the intracellular survival
of the local M. tuberculosis strains or may provide some
selective advantage to them. A recent study using a pro-
moter trap vector has identified two of the genes, moaX
and moeB1 as upregulated in mouse lungs upon infection
[16]. A systematic study is required to understand the
exact role of this protein in the lifecycle of this pathogen.
At the same time, the effect due to the lack of moaA3 on
M. tuberculosis H37Rv may be difficult to quantify as the
remaining array of moa genes could be expected to com-
plement any lost activity.
The RvD5 region from which the amplicon was generated
is an IS6110 mediated deletion in the type strain H37Rv
[7]. IS6110, a powerful genetic marker for strain differen-
tiation [17] has also been shown to play an important role
in mediating genomic rearrangements and deletions in
mycobacteria. In fact, four of the five genomic deletions in
M. tuberculosis H37Rv (except RvD1) are predicted to be
IS6110 mediated recombinations [7]. But IS6110 medi-
ated alterations may not provide much selective advan-
tage to the bacteria from endemic areas such as Kerala, as
a large percentage of the isolates have very few copies of
IS6110 [8]. Insertions and deletions are important in the
evolution of a bacterial species. M. tuberculosis, considered
an evolutionarily "young" pathogen, would not be
expected to have undergone extensive variations in its
genome [18]. But, in spite of this, differences could be
detected between the laboratory strains and clinical iso-
lates, both by sequence analysis as in the case of
CDC1551 [3] and by PCR as in this study. In a scenario of
few/no copies of IS6110  other insertion sequences or
mobile genetic elements could be involved in these varia-
tions. Therefore, a detailed study of the genome of field
strains from different endemic regions would provide
more insights into the diversity of this pathogen.
Conclusion
This study, demonstrates the presence of the moaA3 gene
in a large number of local isolates. This gene has been
shown to be present in M. bovis, but not in H37Rv or
H37Ra. The results obtained suggest that the population
of strains in endemic areas is different from type strains,
as suggested earlier by our analysis of IS6110. The field
strains may also vary between different endemic regions.
So the strains from endemic areas need to be examined in
greater detail to understand the complexities of this path-
ogen. Such an understanding is essential for us to be able
to plan adequate control measures for tackling what is
appearing to be the world's number one killer.
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